Taylor-Robinson, D., Horner, P., & Pallearos, A. (2020). Diagnosis of some genital-tract infections: part 2. Molecular tests and the new challenges. *International Journal of STD and AIDS*.

Peer reviewed version

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via SAGE Publications at https://journals.sagepub.com/doi/abs/10.1177/0956462419890526?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=stda . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Diagnosis of some genital-tract infections: part 2. Molecular tests and the new challenges

David Taylor-Robinson,¹ Patrick Horner^{2,3,4} and Anna Pallearos,⁵

¹Section of Infectious Diseases, Wright-Fleming Institute, Faculty of Medicine, Imperial College London, St Mary's Campus, Norfolk Place, London W2 1PG, UK

²Population Health Sciences, University of Bristol, UK

³National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Evaluation of Interventions in partnership with Public Health England, University of Bristol,

⁴Unity Sexual Health, University Hospitals Bristol NHS Trust, Bristol, UK.

⁵Department of Genito-urinary Medicine, Princess Grace Hospital, 47 Nottingham Place, London W1U 5LZ, UK

Abstract

Promptly and accurately diagnosing genital-tract infections is key to instituting appropriate treatment and control of sexually transmitted infections (STIs). Ano-genital tract testing for STIs in the last two decades has not entirely moved away from insensitive methods but is now at least dominated by highly sensitive molecular methods. These tests can be ordered through the internet for use at home, with self-taken specimens then returned, usually by post, to a clinic or laboratory for testing. The increasing ease of access of the public to this situation, together with increasing online health-seeking behaviour, has resulted in a gap between commercial and NHS management pathways for STIs. Crucially, patients who order multiplex test kits on-line for use at home, and other non-specialists, may not realize that it is worthwhile testing only for *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, and possibly *Trichomonas vaginalis*, and *Mycoplasma genitalium* if the person is symptomatic or their current partner is infected. The detection and recommended treatment of micro-organisms which to some extent are part of the genital-tract microbiome, such as *Mycoplasma hominis*, *Ureaplasma* spp. or *Gardnerella vaginalis*, which do not cause symptoms in the majority of those infected, cannot be recommended. We argue that a shift from specialist led to patient and non-specialist led STI management, in the presence of a clinical leadership vacuum, has increased the risk of inappropriate and unnecessary treatment which will drive macrolide, tetracycline and metronidazole antimicrobial resistance. However, in the past 5-6 years several groups have been able to show the value of on-line testing as a consequence of targeting the most important micro-organisms and using molecular tests to allow rapid and appropriately informed treatment. This should herald a brighter future, although there is still a need for leadership to expertly guide commercial and NHS sectors alike. In turn, this requires

dedicated genito-urinary medicine (GUM) commissioning to be maintained at a time when it appears to be most under threat.

Introduction

We previously gave an historical account of tests used to diagnose six sexually transmitted bacterial infections, and one protozoal, up to the advent of molecular tests.¹ These have now overtaken almost all others at a time when the digital era has seen a revolution in health-seeking behaviour with an unprecedented growth in the commercial market for STI tests. The public may now seek testing and treatment at home with information and access provided online, sometimes without involvement of a STI specialist or NHS provider. Seemingly, this would appear laudable, but it has some unwanted pitfalls. Here, we consider these together with the molecular tests and the impact that the molecular revolution is having on the sexually transmitted disease (STD) field.

Observations on molecular diagnostic tests for the microbes under discussion

Neisseria gonorrhoeae. Currently, the molecular tests used most often to detect *N. gonorrhoeae* are those also set up to detect *C.trachomatis* in the same sample. These are the nucleic acid amplification tests (NAATs) based on a polymerase chain reaction (PCR), namely Roche AMPLICOR and COBAS AMPLICOR;² one based on strand displacement amplification (BDProb Tec; Becton Dickinson)³ and one based on transcription-mediated amplification (TMA): APTIMA Combo 2 (Gen-ProbeInc.).⁴ The cobas CT/NG v2.0 test (Roche Molecular Systems)⁵ behaves comparably to the others mentioned, as does the new Abbott m2000 Real Time CT/NG assay.⁶ The GeneXpertCT/NG assay (Cepheid, Sunnyvale, CA), with similar performance to the aforementioned NAATs produces a result within 1.5 hours. All these methods offer excellent sensitivity, usually well above 90%, while maintaining very high specificity. It is recommended that laboratories confirm any reactive

test with an alternative molecular target if the positive predictive value of the initial test for the population tested is less than 90%.⁷

Chlamydia trachomatis. The licensed NAATs for the detection of *C.trachomatis* are those mentioned above for the detection of *N.gonorrhoeae*. All four assays, as said before, are highly specific and sensitive. Furthermore, where resources are limited, pooling of specimens from different individuals can reduce costs without loss of sensitivity.⁸ The formerly often used Abbott LCx ligase chain reaction test⁹ was withdrawn from the market by the manufacturer in 2003.¹⁰ In 2013, the GeneXpertCT/NG assay (Cepheid, Sunnyvale, CA)¹¹ was the first rapid NAAT shown to have attributes equivalent to recognized commercial NAATs. Therefore, it had the potential for use as a point-of-care (POC) test (*vide infra*) and for revolutionizing genitourinary infection diagnostics.^{12, 13} Recent attention has focused on pooling specimens from the pharynx, rectum and urogenital tract of the same individual at risk of infection in all three sites. This may perform better for detecting *C. trachomatis* than *N.gonorrhoeae*, but more data are needed for firm conclusions.^{12, 13}

Mycoplasma hominis. Real-time PCR technology for *M.hominis* was described first in 2004¹⁴ and, although not always of real-time construction, the PCR has subsequently been an integral part of numerous multiplex tests.¹⁵ Whether they should be used at all is discussed below.

Gardnerella vaginalis. Early molecular studies^{16, 17} showed that *G.vaginalis* belongs to a much larger group of bacterial species that are associated with bacterial vaginosis (BV) than was considered in the pre-molecular era. BV is characterised by depletion of key *Lactobacillus* spp., with an increase in bacterial species diversity and load, including that by *Gardnerella vaginalis*, *Atopobium vaginae* and other BV- associated bacteria (BVAB).¹⁸⁻²² *Atopobium vaginae* is more strongly associated with BV than *G.vaginalis*, the latter detectable by a NAAT in many asymptomatic women.¹⁸⁻²² Therefore, detecting *G.vaginalis*

without considering its load and changes in the composition of other bacteria in the vaginal microbiome cannot be used to accurately diagnose BV. Becton Dickinson²³ have designed and validated a 'vaginitis NAAT' which uses an algorithmic analysis of molecular DNA detection of lactobacilli and four BVAB, including *G.vaginalis*, *Atopobium vaginae* and *Megasphaera spp.*, to diagnose BV with a sensitivity and specificity of >90%, although a study in the UK using the Hay-Ison criteria revealed a specificity of only 79%.²³

Ureaplasma spp. Thirty-eight or more years after detection and quantification of

ureaplasmas by culture, detection, speciation and quantification became possible by using

PCR-based tests.²⁴⁻²⁷ Two species can be identified, namely *Ureaplasma urealyticum* and

U.parvum. *Ureaplasma spp.* are common in the lower genital tract with a greater

U.urealyticum bacterial load, in some men with non-gonococcal urethritis.^{26, 28}

Subsequently, real-time multiplex tests for *Ureaplasma spp.*, *M.hominis* and other micro-

organisms were devised. Whether such tests should be used is considered below.

Mycoplasma genitalium. Subsequent to the difficulty in isolating and culturing

M.genitalium, DNA probes were tried, but these proved insufficiently sensitive. Then in the

late 1980s, two groups^{29,30} each developed a PCR test that was much more sensitive. Each

amplified different fragments of the MgPa adhesin protein and showed that as little as 10⁻¹⁵ g

of *M.genitalium* DNA could be detected This prompted others to use this technique and some

to devise modifications, use a multiplex PCR, target the 16SrRNA gene of *M.genitalium*, and use TMA with success.³¹ Molecular methods have also shown an increase in the prevalence of *M.genitalium* resistance to several antibiotics, particularly macrolides (*vide infra*).³² The latter is probably due to extensive use of azithromycin 1g to treat chlamydial infections and non-gonococcal urethritis.³² There are now at least two satisfactorily sensitive, FDA-approved, commercial assays, available, namely the Aptima TMA assay (Hologic Ltd)³³ and the Speedx ResistancePlus MG assay which also tests for macrolide resistance.³⁴ The new guidelines³² of the British Association for Sexual Health and HIV (BASHH) for *M.genitalium* recommend testing patients with urethritis and pelvic inflammatory disease, and current sexual contacts and, if positive, testing for macrolide resistance-mediating mutations. This will improve clinical outcomes and reduce the risk of resistance to both macrolides and quinolones in the United Kingdom. There is no recommendation to screen asymptomatic individuals.

***Trichomonas vaginalis*.** Although some non-molecular diagnostic tests, for example, the OSOM rapid test,³⁵ are used for convenience, NAATs out-perform all others.³⁶ Thus, the TMA-based APTIMA TV test^{37,38}, although not the only molecular one,³⁹ is highly sensitive, FDA-approved and widely used, particularly as it fits into settings where gonococcal and chlamydial molecular tests are in place. Becton Dickinson have developed a multiplex format for simultaneous detection of *N.gonorrhoeae* and *C.trachomatis* which performs well in accurately detecting all three infections.⁴⁰ The TV assay has also been incorporated in its vaginitis assay with no apparent loss in performance.⁴¹

Issues around point-of-care (POC) tests

A POC test has come to mean one in which a specimen is examined in a sensitive and rapid procedure close enough to the patient to let treatment begin with little waiting. We have mentioned before¹ that efforts to produce a rapid, specific and sensitive non-molecular POC

test for *C.trachomatis* failed, largely due to inadequate sensitivity. Furthermore, the notion by some that a test with a sensitivity less than desired, but allowing rapid treatment, is preferable to a slower NAAT of greater sensitivity belongs firmly to a bygone era. The view that POC tests should increasingly form the diagnostic approach of the future,⁴² has gained greater credibility due to the development of rapid NAATs. Modelling suggests that the introduction of such technology in sexual health clinics, including targeted multiplex testing, could be cost effective, and clinical evidence to support this is beginning to emerge.⁴³⁻⁴⁵ Thus, the GenXpert CT/NG molecular test when used on asymptomatic patients attending a rapid testing service (Dean Street Express) provided results, compared with those for patients attending an existing sexual health clinic, that were faster and enabled faster treatment, fewer partner transmissions and reduced clinic costs due to fewer partner attendances.⁴⁶ The same molecular test has also been used successfully when conducted routinely as a POC test by clinicians in remote primary healthcare settings.⁴⁷ Looking to the future, these POC tests will also be able to detect antimicrobial resistance, enabling diagnosis and individualised treatment at the first health care visit, potentially reducing selection pressure on recommended antimicrobials, reducing transmission of resistant strains and providing a means of surveying resistance.⁴⁸ Thus, the introduction of POC testing seems admirable if clinicians are fully aware of the complexities of treatment and can provide it quickly, knowing that it is based on an accurate microbiological diagnosis.

Multiplex test dilemma

Outside the NHS, there is increased testing by the public. They are vulnerable to multiplex assays being relatively cheap and to a commercial imperative to do as much testing as possible but, doubtless, bewildered by assays for as many as 12 different micro-organisms/conditions. Some companies recommend testing for asymptomatic infections and most suggest treatment for all subjects with positive results. The notion that the public,

without considerable help, can choose the correct tests and receive appropriate treatment is beyond imagination. Several commercial multiplex NAATs, which include detection for gonococcal and chlamydial infections, are available and CE marked. However, it is a concern that there is very limited comparative information in peer reviewed journals for most promoted assays regarding their performance in detecting these infections. Further comments about multiplex tests for *Ureaplasma* spp., *G.vaginalis* and other microbes are made later.

Home on-line screening and treatment

Diagnostic and treatment services of apparent merit

In view of the previous comments, it may seem ironic to say that better involvement of the public in their own care should be a laudable approach to tackling the increasing existence of STDs; home-based tests should empower the individual. Furthermore, it cannot be denied that the increased use of on-line services in the UK and elsewhere.⁴⁹ should theoretically help to ease the tension in understaffed and underfunded NHS GUM clinics. In the last dozen years, particularly in the last five to six, there has been a variety of on-line providers⁵⁰⁻⁵⁵ that have supported screening and treatment services above and beyond those provided by attending NHS clinics. Success is attributable to the in-put of both physician and laboratory staff and to pin-pointing micro-organisms regarded as the most important. Thus, *N.gonorrhoeae* and *C.trachomatis* detection using NAATs has almost always been a feature and, usually, serology to diagnose syphilis and HIV infection. It is imperative that as the provision of on-line testing continues to expand, only appropriate testing and treatment are recommended and that there is a move away from promoting testing for micro-organisms for which there is no evidence that testing does more good than harm, so increasing the risk of antimicrobial resistance. Commercial on-line testing may also compromise an understanding of the true prevalence of infection by public health authorities, unless they are mandated to

contribute anonymised data to the national STI and HIV statistics produced by Public Health England.

New diagnostic NAATs will include POC tests which will enable assessment of antimicrobial resistance, and multiplex options too ⁴⁸. The most recent example is that for *M.genitalium* with macrolide resistance testing, the use of which has been shown to prevent the emergence of antimicrobial resistance in this mycoplasma.³² However, funding for such tests is a major concern, given the decrease in funding for sexual health services (vide infra).

Screening and treatment services with apparent flaws

Tests for the micro-organisms detailed above are accessible ‘on-line’ from innumerable commercial web-sites. These can be offered as both screening and diagnostic tests. This easy access to molecular testing for the public has resulted in a gap between the commercial and NHS diagnostic testing pathways. The public who initiate testing on-line should be aware that poorly performing, insensitive, POC tests for *C.trachomatis*, seen repeatedly for close on a decade, ⁵⁶ still exist. These “CE approved” tests, including that for gonorrhoea, are most often lateral flow immunoassays providing a result within 10-15 minutes. This implies an inferior sensitivity to molecular tests.^{57, 58} Promotional material suggests that the accuracy of some tests is >98%, although what limited external validation against a NAAT there is ⁵⁹ indicates a performance substantially below that stated in the package insert.⁵⁸ Such tests can be purchased on-line in the United Kingdom and internationally ⁶⁰ and are cheaper than the home-based NAATs (see above). The current commercial multiplex assays where specimens are sent to a laboratory for testing may be relatively cheap, but the wide range of different micro-organisms (up to 12) represented in the ‘one size fits all’ test profiles may attract the biggest market, rather than have the best clinical application. The public should be advised that testing is only worthwhile for *N.gonorrhoeae* and *C.trachomatis*, and in women possibly *T.vaginalis*, which has been reported to cause infection only rarely in the UK, although

associated with black minority ethnicity and deprivation in some parts.⁶¹ *M.genitalium* is also worth testing for⁶², but only if the patient is symptomatic or their current partner is infected. Screening of asymptomatic men cannot be recommended in the absence of randomized controlled trials demonstrating cost effectiveness.⁶³ The need for controlled trials before screening for *M.genitalium* can be advised is also seen, for example, in women with reproductive problems.⁶⁴ This note of caution contrasts with the notion that there is little or no need to test for the presence of some other micro-organisms. Thus, *M.hominis* has never been shown to cause urethritis or other significant disease in men and its recovery from the vagina, cervix or urine is very difficult to relate to any problem in the upper genital tract.⁶⁵ While a strong association with BV is undoubted, it has never been shown to be a cause in itself. Also, a positive test for *Ureaplasma* spp. in asymptomatic men and women does not deserve attention. However, testing for *U.urealyticum* may be appropriate in men with symptoms and signs of urethritis⁶⁶ although only if indisputable pathogens have been excluded and the organism load is large, as this species is probably only causal in 20-60% when it is associated with a high load.^{28,67} In women, as is the case for *M.hominis*, detection of either *Ureaplasma* spp. in the vagina, cervix or urine has never been related significantly to a problem in the upper genital tract, or to the painful bladder syndrome, the urethral syndrome or infertility.⁶⁸ A positive role for ureaplasmas in chronic lung disease of extremely low birth-weight infants has some support,^{68,69} but evidence for their involvement in preterm delivery is less convincing⁶⁸ despite a report⁷⁰ of a more promising association based on aggressive antibiotic therapy. Nevertheless, in both lung disease and premature delivery nothing has been published to justify routine antibiotic therapy to prevent mother to baby transmission. Whether large, rather than small, numbers of these organisms might be associated with any of the diseases mentioned is a logical but insufficiently tested notion. Hence, until there are definitive answers, there is no logic in screening or testing

asymptomatic or symptomatic men and women for *M.hominis*, *U.urealyticum* or *U.parvum*, unless, of course, ureaplasmas are being sought as part of a research investigation. Indeed, the expert view²⁸ is that it is unquestionably inappropriate to treat just because these organisms have been detected in the lower genital tract. Nevertheless, there are commercial services currently recommending treatment with doxycycline, azithromycin and both sequentially when these micro-organisms are detected in single assays or as part of a multiplex array. Thus, the virtue of having these tests available on-line must be questioned, particularly as it is known that antibiotics may dramatically change the gut and oral microbiomes⁷¹ and doubtless the genital-tract microbiome too. So far as *G.vaginalis* is concerned, there seems little point in having it alone in a multiplex array for diagnosing BV when other bacteria, mentioned above, are more strongly associated with BV. A molecular test⁷² that takes into account various bacteria encountered in BV would seem to have more merit. Of course, tests on vaginal smears for their cellular composition^{73,74} is a laboratory undertaking without patient involvement at home.

The issues considered are important because a positive PCR test may fuel fears of infection and infectivity among the public and health professionals alike. This is particularly so if reference is made to sexually transmitted infection / disease⁷⁵ and when positivity may not mean that the micro-organism in question is responsible for the symptoms and, therefore, may not imply treatment. Antibiotics may offer false assuagement of resultant patient distress. Not understanding what antibiotic is required⁷⁶ or failing to take heed of management guidelines for non-gonococcal urethritis,^{77,78} *N.gonorrhoeae*⁷⁹ or *M.genitalium*,⁸⁰ and/or a lack of understanding that *M.hominis*, *U.urealyticum* and *U.parvum* can be difficult to eradicate, may have an untoward outcome, namely over-prescribing or providing a wrong antibiotic when the need for effective antibiotic stewardship is an international priority. The extensive treatment for the latter microbes, mainly commensals,

with suboptimal antimicrobial regimens selects for resistance not only in them, but also in *N.gonorrhoeae* and *M.genitalium*. Thus, although a novel electronic messaging treatment service for *C.trachomatis* at a community pharmacy with the use of azithromycin 1g ⁸¹ might seem attractive, it has to be weighed against fostering macrolide-resistance in *M.genitalium*. Indeed, the spectre of high-grade resistance by gonococci to macrolides ⁸² and most recently to both azithromycin and ceftriaxone ⁸³ and *M.genitalium* to macrolides and other antibiotics ⁸⁴⁻⁹² is with us. In the case of the latter micro-organism, pristinomycin may be the only antibiotic effective for some patients.⁹³ It is not surprising to learn that syndromic management may fail ⁹⁴ and empiric treatment needs to be reconsidered ^{95,96} as a result of antimicrobial resistance. ⁹⁷ Furthermore, increasingly led by non-specialists, commercial services may sometimes not involve a GUM specialist until repeated courses of antibiotics lead to iatrogenic harm, including antibiotic-associated candidiasis. This must not be allowed to continue. A micro-organism already antibiotic resistant or that has developed resistance during treatment may not be catered for adequately. Although it is theoretically possible that prolonged sub-inhibitory concentrations of azithromycin intra- and extra-cellularly after treatment of a gonococcal infection leads to resistance, evidence that previous exposure leads to resistance by this means is conflicting.^{98,99} This is in contrast to *M.genitalium*, the resistance of which, as noted, is influenced in this way.

What should be done?

It is imperative that inappropriate and unnecessary testing for sexually transmitted micro-organisms by commercial on-line companies needs to be regulated to ensure that there is a move away from promoting increased antimicrobial resistance. Achieving this can be helped by educating the public, particularly those with self-diagnosis and treatment in mind, as to what is right and wrong by information provided simply, both on-line and in clinics, and by maintaining GUM commissioning with a remit to lead and disseminate NICE-accredited

guidance for both the commercial and NHS sectors. The crucial nature of this is emphasized by the fact that on the 13th July 2018 the British Association of Sexual Health and HIV (BASHH) launched new NICE-accredited treatment guidelines for *M.genitalium* ³² in an attempt to prevent it becoming a ‘superbug’ within 10 years. At the same time, however, seven in ten sexual health experts said they could not afford diagnostic tests recommended by the guidelines and only one in ten UK public health commissioners said they were making provisions for testing equipment in their 2019 budget.

Conclusions

First, for those who intend that diagnosis should start at home, the aim should be procurement of appropriate specimens that are sent under guided instruction to laboratories equipped with rapid and highly sensitive tests, followed by physician-guided treatment. In some areas in the UK and elsewhere an on-line approach to diagnosis and treatment has been developed to good effect and these ventures should be seen as role models for others in the field. The use of very rapid NAATs ^{11, 46, 100} must be a virtue, but speed associated with such a POC test may be less important than having a knowledgeable and thoughtful approach to treatment based on the correct laboratory result; the latter should be aided by adherence to the appropriate BASHH guideline. ^{7, 32} Second, it might appear that the issues are being discussed without positive action being taken. However, it would be churlish to believe this when one of us (PH) attended a Parliamentary Roundtable meeting on Sexual Health and AMR (3rd April 2019).¹⁰¹ Nevertheless, further thought should be given to how expert clinical leadership can be improved with a view to regulatory change. There should be a multi-agency approach involving key stakeholders with the remit to guard against the use of insensitive and inappropriate tests and help to maintain further improvements in the diagnostic scene. Thus, it would be laudable to discourage testing for *M.hominis*, *G.vaginalis*, and *Ureaplasma* spp., when positive results have little or no meaning, unless the person is male and has urethritis and quantitative testing

for *U.urealyticum* is available. Third, it would seem appropriate to develop NHS-accredited information leaflets for providers and the public on the use of molecular tests, the significance of results and the most appropriate treatment. Certainly, on-line self-diagnosis has improved, but pitfalls mentioned here should not go unchecked. There is still an opportunity to further harness molecular diagnostics towards best patient care, good medical practice, improved research and avoidance of further antibiotic resistance. Fourthly, with increasing antibiotic resistance of *N.gonorrhoeae* and *M.genitalium* in mind, efforts should be made to encourage the development and testing of vaccines.^{102, 103} Prevention is better than cure.

Acknowledgement: This work was supported by the NIHR Health Protection Research Unit in Evaluation of Interventions at the University of Bristol. PH is a Co-Director of Sexual Health Improvement Programme (SHIP), Bristol Health Partners. The views expressed are those of the authors.

References

1. Taylor-Robinson D, Pallearos A, Horner P. Diagnosis of some genital-tract infections: part 1. An historical perspective. *Int J STD AIDS* 2017; 28: 1143-1149.
2. Martin DH, Cammarata C, Van der Pol B, et al. Multicenter evaluation of the AMPLICOR and automated COBAS AMPLICOR CT/NG tests for *N.gonorrhoeae*. *J Clin Microbiol* 2000; 38: 3544-3549.
3. Van der Pol B, Ferrero D, Buck-Barrington L, et al. Multicenter evaluation of the BD Probe Tec ET system for the detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in urine specimens, female endocervical swabs, and male urethral swabs. *J Clin Microbiol* 2001; 39: 1008-1016.
4. Gaydos CA, Quinn TC, Willis D, et al. Performance of the APTIMA Combo 2 assay for

- the multiplex detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in female urine and endocervical swab specimens. *J Clin Microbiol* 2003; 41: 304-309.
5. Nye MB, Osiecki J, Lewinski M, et al. Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* with cobas CT/NG v2.0 test: performance compared with the BD ProbeTec CT Q^x and GC Q^x amplified DNA and Aptima AC2 assays. *Sex Transm Infect* 2019; 95: 87-93.
 6. Cherkaoui A, Renzi G, Mombelli M, et al. Comparison of analytical performances of the Roche Cobas 6800 CT/NG assay with the Abbott m2000 Real Time CT/NG assay for detecting *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. *J Med Microbiol* 2019; 68:197-200.
 7. Fifer H, Saunders J, Soni S, et al. BASHH national guideline for the management of infection with *Neisseria gonorrhoeae* 2019. Update Jan 20th.
 8. Peeling RW, Toye B, Jessamine P, et al. Pooling of urine specimens for PCR testing: a cost saving strategy for *Chlamydia trachomatis* control programmes. *Sex Transm Infect* 1998;74: 66-70.
 9. Taylor-Robinson D. Tests for infection with *Chlamydia trachomatis*. *Int J STD AIDS* 1996;7: 19-26.
 10. Mallinson H, Hopwood J, Mutton K. Resolution of the recent performance problem of Abbott LCx *Chlamydia trachomatis* assay. Issues of repeat testing for confirmation of chlamydial infection. *Sex Transm Infect* 2002; 78: 225-226.
 11. Gaydos CA, Van der Pol B, Jett-Goheen M, et al. Performance of the Cepheid CT/NG Xpert Rapid PCR test for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*. *J Clin Microbiol* 2013; 51: 1666-1672.
 12. Adams EJ, Ehrlich A, Turner KME, et al. Mapping patient pathways and estimating resource use for point of care versus standard testing and treatment of chlamydia and

- gonorrhoea in genitourinary medicine clinics in the UK. *BMJ Open* 2014; 4 (7).
13. Turner KME, Round J, Horner P, et al. An early evaluation of clinical and economic costs and benefits of implementing point of care NAAT tests for *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in genitourinary medicine clinics in England. *Sex Transm Infect* 2014; 90:104-111.
14. Baczynska A, Svenstrup HE, Fedder J, et al. Development of real-time PCR for detection of *Mycoplasma hominis*. *BMC Microbiol* 2004; 4: 35.
15. McIver CJ, Rismanto N, Smith C, et al. Multiplex PCR testing detection of higher-than-expected rates of cervical mycoplasma, ureaplasma and trichomonas and viral infections in sexually active Australian women. *J Clin Microbiol* 2009; 47:1358-1363.
16. Fredricks DN, Fiedler TL, Marrazzo JM: Molecular identification of bacteria associated with bacterial vaginosis. *New Eng J Med* 2005; 353 :1899-1911.
17. Menard J-P, Fenoller F, Henry M, et al. Molecular quantification of *Gardnerella vaginalis* and *Atopobium vaginae* loads to predict bacterial vaginosis. *Clin Infect Dis* 2008;47: 33-43.
18. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. *Proc Nat Acad Sci* 2011; 108: Suppl 1-4680.
19. Martin DH: The microbiota of the vagina and its influence on women's health and disease. *Amer J Med Sci* 2012; 343: 2-9.
20. Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis - striving for long-term cure. *BMC Infect Dis* 2015; 15: 292.
21. Gaydos CA, Beqaj S, Schwebke JR, et al. Clinical validation of a test for the diagnosis of vaginitis. *Obstet Gynecol* 2017; 130 :181-189.
22. Schwebke JR, Gaydos CA, Nyirjesy P, et al. Diagnostic performance of a molecular test versus clinician assessment of vaginitis. *J Clin Microbiol* 2018; 56.

23. Sherrard J: Evaluation of the BD MAX Vaginal Panel for the detection of vaginal infections in a sexual health service in the UK. *Int J STD AIDS* 2019; 30: 411-414.
24. Deguchi T, Yoshida T, Miyazawa T, et al. Association of *Ureaplasma urealyticum* (biovar 2) with nongonococcal urethritis. *Sex Transm Dis* 2004; 31:192-195.
25. Mallard K, Schoffer K, Bodmer T. Development of real-time PCR for the differential detection and quantification of *Ureaplasma urealyticum* and *Ureaplasma parvum*. *J Microbiol Methods* 2005; 60: 11-39.
26. Shimada Y, Ito S, Mizutani K, et al. Bacterial loads of *Ureaplasma urealyticum* contribute to development of urethritis in men. *Int J STD AIDS* 2014; 25: 294-298.
27. Deguchi T, Shimada Y, Horie K, et al. Bacterial loads of *Ureaplasma parvum* contribute to the development of inflammatory responses in the male urethra. *Int J STD AIDS* 2014; 26:(e-pub).
28. Horner P, Donders G, Cusini M, et al. Should we be testing for urogenital *Mycoplasma hominis*, *Ureaplasma parvum* and *Ureaplasma urealyticum* in men and women? -- a position statement from the European STI Guidelines Editorial Board. *J Eur Acad Dermatol Venereol* 2018;
29. Palmer HM, Gilroy CB, Furr PM, et al. Development and evaluation of the polymerase chain reaction to detect *Mycoplasma genitalium*. *FEMS Microbiol Lett* 1991; 61: 199-203.
30. Jensen JS, Uldum SA, Søndergård-Andersen J, et al. Polymerase chain reaction for detection of *Mycoplasma genitalium* in clinical samples. *J Clin Microbiol* 1991; 29: 46-50.
31. Taylor-Robinson D, Jensen JS. *Mycoplasma genitalium*: from chrysalis to multicolored butterfly. *Clin Microbiol Rev* 2011; 24: 498-514.
32. Soni S, Horner P, Rayment M, et al. British Association for Sexual Health and HIV

- national guideline for the management of infection with *Mycoplasma genitalium* (2018). *Int J STD AIDS* 2019; 30: 938-950.
33. Tabrizi SN, Costa AM, Su J, et al. Evaluation of the Hologic Panther transcription mediated amplification assay for detection of *Mycoplasma genitalium*. *J Clin Microbiol* 2016; 54: 2201-2203.
34. Su JP, Tan LY, Garland SM, et al. Evaluation of the SpeeDx ResistancePlus MG diagnostic test for *Mycoplasma genitalium* on the Applied Biosystems 7500 Fast Quantitative PCR Platform. *J Clin Microbiol* 2018; 56.
35. Nathan B, Appiah J, Saunders P, et al. Microscopy outperformed in a comparison of five methods for detecting *Trichomonas vaginalis* in symptomatic women. *Int J STD AIDS* 2015; 26: 251-256.
36. Van der Pol B. Clinical and laboratory testing for *Trichomonas vaginalis* infection. *J Clin Microbiol* 2016; 54:7-12.
37. Nye MB, Schwebke JR, Body BA. Comparison of APTIMA *Trichomonas vaginalis* transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. *Am J Obstet Gynecol* 2009; 200: 188.e 1-7.
38. Nicholls JE, Turner KME, North P, et al. Cross-sectional study to evaluate *Trichomonas vaginalis* positivity in women tested for *Neisseria gonorrhoeae* and *Chlamydia trachomatis*, attending genitourinary medicine and primary care clinics in Bristol, South West England. *Sex Transm Infect* 2018; 94: 93-99.
39. Tipple C, Rayment M, Mandalia S, et al. An evaluation study of the Becton-Dickinson ProbeTec Qx (BDQx) *Trichomonas vaginalis* trichomoniasis molecular diagnostic test in two large, urban STD services. *Sex Transm Infect* 2018; 94: 334-336.
40. Van der Pol B, Williams JA, Fuller D, et al. Combined testing for Chlamydia, Gonorrhea,

- and *Trichomonas* by use of the BD Max CT/GC/TV assay with genitourinary specimen types. *J Clin Microbiol* 2017; 55:155-164.
41. Van der Pol B, Daniel G, Kods S, et al. Molecular-based testing for sexually transmitted infections using samples previously collected for vaginitis diagnosis. *Clin Infect Dis* 2019; 68: 375-381.
42. Toskin I, Peeling RW, Mabey D, et al. Point-of-care tests for STIs: the way forward. *Sex Transm Infect* 2017; 93: S1-2.
43. Turner KME, Round J, Horner P, et al. An early evaluation of clinical and economic costs and benefits of implementing point of care NAAT tests for *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in genitourinary medicine clinics in England. *Sex Transm Infect* 2014; 90: 104-111.
44. Adams EJ, Ehrlich A, Turner KME, et al. Mapping patient pathways and estimating resource use for point of care versus standing testing and treatment of chlamydia and gonorrhoea in genitourinary medicine clinics in the UK. *BMJ Open* 2014; 4(7): e005322.
45. Huntington SE, Burns RM, Harding-Esch E, et al. Modelling-based evaluation of the costs, benefits and cost-effectiveness of multipathogen point-of-care tests for sexually transmitted infections in symptomatic genitourinary medicine clinic attendees. *BMJ Open* 2018; 8(9): e020394.
46. Whitlock GG, Gibbons DC, Longford N, et al. Rapid testing and treatment for sexually transmitted infections improve patient care and yield public health benefits. *Int J STD AIDS* 2018; 29: 474-482.
47. Causer LM, Guy RJ, Tabrizi SN, et al. Molecular test for Chlamydia and gonorrhoea used at point of care in remote primary healthcare settings: a diagnostic test evaluation. *Sex Transm Infect* 2018; 94: 340-345.

- 48.Sadiq ST, Mazzaferri F, Unemo M. Rapid accurate point-of-care tests combining diagnostics and antimicrobial resistance prediction for *Neisseria gonorrhoeae* and *Mycoplasma genitalium*. *Sex Transm Infect* 2017; 93: S65-S68.
- 49.Wilson E, Free C, Morris TP, et al. Internet-accessed sexually transmitted infection (e-STI) testing and results service. A randomized, single-blind, controlled trial. *PLOS Med* 2017;14: 21002479.
- 50.Gaydos, Dwyer K, Barnes M, et al. Internet screening for *Chlamydia trachomatis* to reach non-clinic populations with mailed self-administered vaginal swabs *Sex Transm Dis* 2006; 33: 451-457.
- 51.Novak D and Novak M. Use of the Internet for home testing for *Chlamydia trachomatis* in Sweden: who are the users? *Int J STD AIDS* 2012; 23: 83-87.
- 52.Odesanmi TY, Wasti SP, Odesanmi OS, et al. Comparative effectiveness and acceptability of home-based and clinic-based sampling methods for sexually transmissible infections screening in females aged 14-50 years in systematic review and meta-analysis. *Sex Health* 2013; 10: 559-569.
- 53.Barnard S, Free C, Bakolis I, et al. Comparing the characteristics of users of an online service for STI self-sampling with clinic service users: a cross-sectional analysis. *Sex Transm Infect* 2018: 10.1136/sextrans-2017-053302.
- 54.Gilbert M, Thomson K, Salway T, et al. Differences in experiences of barriers to STI testing between clients of the internet-based diagnostic testing service GetCheckedOnline.com and an STI clinic in Vancouver, Canada. *Sex Transm Infect* 2018: 10.1136/sextrans-2017-053325.
- 55.Syred J, Holdsworth G, Howroyd C, et al. Choose to test: self-selected testing for sexually transmitted infections within an online service. *Sex Transm Infect* 2019: 10.1136/sextrans2018-053796.

56. Schachter J. Point-of-care tests using enzyme detection to diagnose *Chlamydia trachomatis* infection do not work. But when they fail in clinical trials, they reappear under different names. *Sex Transm Infect* 2016; 92: 406-407.
57. Skidmore S, Horner P, Herring A, et al. Vulvovaginal-swab or first-catch urine specimen to detect *Chlamydia trachomatis* in a community setting? *J Clin Microbiol* 2006; 44: 4389-4394.
58. Stephen S, Munchaneta-Kubara CGE, Munjoma MW, et al. Evaluation of Cortez OneStep Chlamydia Rapicard Insta test for the detection of *Chlamydia trachomatis* in pregnant women at Mbare Polyclinic in Harare, Zimbabwe. *Int J MCH AIDS* 2017; 6: 19-26.
59. Black CM. Current methods of laboratory diagnosis of *Chlamydia trachomatis* infections. *Clin Microbiol Rev* 1997; 10: 160-184.
60. den Daas C, Sukel B, Bos H, et al. Evaluation and enumeration of online test providers for sexually transmitted infections, specifically chlamydia, in the Netherlands. *Sex Transm Infect* 2018; 0537771:1-6.
61. Field N, Clifton S, Alexander S, et al. *Trichomonas vaginalis* infection is uncommon in the British general population: implications for clinical testing and public health screening. *Sex Transm Infect* 2018; 94: 226-229.
62. Golden MR, Workowski KA, Bolan G. Developing a public health response to *Mycoplasma genitalium*. *J Infect Dis* 2017; 216 (Suppl 2): 420-426.
63. Horner PJ, Martin DH. *Mycoplasma genitalium* infection in men. *J Infect Dis* 2017; 216 (Suppl 2): 396-405.
64. Wiesenfeld HC, Manhart LE. *Mycoplasma genitalium* in women: current knowledge and research priorities for this recently emerged pathogen. *J Infect Dis* 2017; 216(Suppl 2): 389-395.

65. Taylor-Robinson D, Jensen JS, Svenstrup H, et al. Difficulties experienced in defining the microbial cause of pelvic inflammatory disease. *Int J STD AIDS* 2012; 23:18-24.
66. Wetmore CM, Manhart LE, Lowens MS, et al. *Ureaplasma urealyticum* is associated with nongonococcal urethritis among men with fewer lifetime sexual partners: a case control study. *J Infect Dis* 2011; 204: 1274-1282.
67. Zhang N, Wang R, Li X, et al. Are *Ureaplasma* spp. a cause of nongonococcal urethritis? A systematic review and meta-analysis. *PLoS ONE* 2014; 9: e113771.
68. Taylor-Robinson D. The role of mycoplasmas in pregnancy outcome. *Best Pract Res Clin Obstet Gynaecol* 2007; 21: 425-438.
69. Bowman ED, Dharmalingham A, Fan WQ, et al. *Ureaplasma urealyticum* respiratory tract colonization and chronic lung disease in infants with very low birth weight. *Prenat Neonat Med* 1997; 2: 42-47.
70. Lee J, Romero R, Kim SM, et al. A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM. *J Maternal-Fetal Neonat Med* 2016; 29: 707-720.
71. Shaw LP, Basham H, Barnes CP, et al. Modelling microbiome recovery after antibiotics using a stability landscape framework. *Int Soc Microb Ecol J* 2019; 13: 1845-1856.
72. Dols JAM, Molenaar D, van der Helm JJ, et al. Molecular assessment of bacterial vaginosis by *Lactobacillus* abundance and species diversity. *BMC Infect Dis* 2016; 16: 180.
73. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standard method of Gram stain interpretation. *J Clin Microbiol* 1991; 29: 297-301.
74. Ison CA, Hay PE. Validation of a simplified grading of Gram stained vaginal smears for

- use in genitourinary medicine clinics. *Sex Transm Infect* 2002;78: 413-415.
75. Taylor-Robinson D, Horner P, Pallearos A. The terms we use: support for the use of sexually shared microbiota (SSM). *Int J STD AIDS* 2019. In press.
 76. Horner P, Ingle SM, Garrett F, et al. Which azithromycin regimen should be used for treating *Mycoplasma genitalium*? A meta-analysis. *Sex Transm Infect* 2018; 94: 14-20.
 77. Horner PJ, Blee K, O'Mahony C, et al. 2015 UK National Guideline on the management of non-gonococcal urethritis. *Int J STD AIDS* 2016; 27: 85-96.
 78. Horner PJ, Blee K, Falk L, et al. 2016 European guideline on the management of non-gonococcal urethritis. *Int J STD AIDS* 2016; 27: 928-937.
 79. WHO guidelines for the treatment of *Neisseria gonorrhoeae*. World Health Organization 2016. <http://www.who.int>
 80. Jensen JS, Cusini M, Gomberg M, et al. 2016 European guideline on *Mycoplasma genitalium* infections. *J Eur Acad Dermatol Venereol* 2016; 30: 1650-1656.
 81. Willetts SJ, Cowper S, Cameron ST. An audit of a novel electronic messaging treatment service for *Chlamydia trachomatis* at a community pharmacy. *Int J STD AIDS* 2008; 29: 511-514.
 82. Unemo M, del Rio C, Shafer WM. Antimicrobial resistance expressed by *Neisseria gonorrhoeae*: a major global health problem in the 20st century. *Microb Spectr* 2016; 4 Jun 24.
 83. Two cases of resistant gonorrhoea diagnosed in the UK. Public Health England. 2019 Jan 9th.
 84. Horner PJ. Azithromycin antimicrobial resistance and *Chlamydia trachomatis* infection: duration of therapy may be the key to improving efficacy. *Sex Transm Infect* 2012; 88: 154-156.
 85. Tagg KA, Jeoffreys NJ, Couldwell DL, et al. Fluoroquinolone and macrolide resistance-

- associated mutations in *Mycoplasma genitalium*. *J Clin Microbiol* 2013; 51: 2245-2249.
86. Couldwell DL, Tagg KA, Jeoffreys NJ, et al. Failure of moxifloxacin in treatment of *Mycoplasma genitalium* infections due to macrolide and fluoroquinolone resistance. *Int J STD AIDS* 2013; 24: 822-828.
87. Yamaguchi Y, Takei M, Kishii R, et al. Contribution of topoisomerase IV mutation to quinolone resistance in *Mycoplasma genitalium*. *Antimicrob Agents Chemother* 2013; 57: 1772-1776.
88. Horner P, Blee K, Adams E. Time to manage *Mycoplasma genitalium* as an STI: but not with azithromycin 1 g! *Curr Opin Infect Dis* 2014; 27: 68-74.
89. Pond MJ, Nori AV, Witney AA, et al. High prevalence of antibiotic-resistant *Mycoplasma genitalium* in non-gonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. *Clin Infect Dis* 2013; 58: 631-637.
90. Dumke R, Thurmer A, Jacobs E. Emergence of *Mycoplasma genitalium* strains showing mutations associated with macrolide and fluoroquinolone resistance in the region of Dresden, Germany. *Diagn Microbiol Infect Dis* 2016; 86: 221-223.
91. Pitt R, Fifer H, Woodford N, et al. Detection of markers predictive of macrolide and fluoroquinolone resistance in *Mycoplasma genitalium* from patients attending sexual health services in England. *Sex Transm Infect* 2018; 94: 9-13.
92. Couldwell DL, Jalocon D, Power M, et al. *Mycoplasma genitalium*: high prevalence of resistance to macrolides and frequent anorectal infection in men who have sex with men in western Sydney. *Sex Transm Infect* 2018; 94: 406-410.
93. Soni S, Parkhouse A, Dean G. Macrolide and quinolone-resistant *Mycoplasma genitalium* in a man with persistent urethritis: the tip of the British iceberg? *Sex Transm Infect* 2017; 93: 556-557.
94. Maduna LD, Lauman JGE, Radebe O, et al. Failure of syndromic management due to

- drug-resistant *Mycoplasma genitalium* infection in South Africa; a case report. *Int J STD AIDS* 2019; Feb 4th. <https://doi.org/10.1177/0956462418820745>.
95. Bjornelius E, Magnusson C, Jensen JS. *Mycoplasma genitalium* macrolide resistance in Stockholm, Sweden. *Sex Transm Dis* 2017; 93:167-168.
96. Pearce E, Chan DJ, Smith DE. Empiric antimicrobial treatment for asymptomatic sexual contacts of sexually transmitted infection in the era of antimicrobial resistance: time to rethink? *Int J STD AIDS* 2018 Oct 6th <http://doi.org/10.1177/0956462418799181>.
97. Pitt R, Cole MJ, Fifer H, et al. Evaluation of the *Mycoplasma genitalium* Resistance Plus kit for the detection of *M. genitalium* and mutations associated with macrolide resistance. *Sex Transm Infect* 2018; 94:565-567.
98. Wind CM, de Vries E, van der Loeff MF, et al. Decreased azithromycin susceptibility of *Neisseria gonorrhoeae* isolates in patients recently treated with azithromycin. *Clin Infect Dis* 2017;65: 37- 45.
99. Clifton S, Town K, Furegato M, et al. Is previous azithromycin treatment associated with azithromycin resistance in *Neisseria gonorrhoeae*? A cross-sectional study using national surveillance data in England. *Sex Transm Infect* 2018; 94: 421-426.
100. Brook G. The performance of non-NAAT point-of-care (POC) tests and rapid NAAT tests for chlamydia and gonorrhoea infections. An assessment of currently available assays. *Sex Transm Infect* 2015; 91: 539-544.
101. Parliamentary Roundtable Meeting on Sexual Health and AMR: Antimicrobial resistance and sexual health—addressing growing levels of resistance and ensuring effective stewardship. April 3rd 2019.
102. Hobbs MM, Sparling PF, Cohen MS, et al. Experimental gonococcal infection in male volunteers: cumulative experience with *Neisseria gonorrhoeae* strains FA 1090 and MS 11mkC. *Front Microbiol* 2011; 2: 123.

103. Taylor-Robinson D. Diagnosis and antimicrobial treatment of *Mycoplasma genitalium* infection: sobering thoughts. *Expert Rev Anti Infect Ther* 2014; 12: 715-722.